Advertisement

Journal of General Internal Medicine

, Volume 34, Issue 12, pp 2772–2778 | Cite as

Low Awareness of Nonalcoholic Fatty Liver Disease in a Population-Based Cohort Sample: the CARDIA Study

  • Erin R. Cleveland
  • Hongyan Ning
  • Miriam B. Vos
  • Cora E. Lewis
  • Mary E. Rinella
  • John Jeffrey Carr
  • Donald M. Lloyd-Jones
  • Lisa B. VanWagnerEmail author
Original Research

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the United States, yet little is known about NAFLD awareness in individuals with incidental fatty liver on imaging.

Objective

To assess the level of awareness of imaging-defined NAFLD among individuals with and without metabolic risk factors.

Design

Cross-sectional analysis within a prospective longitudinal population-based cohort study conducted in four U.S. cities.

Participants

Adults age 43 to 55 years enrolled in the Coronary Artery Risk Development in Young Adults (CARDIA) Study who underwent computed tomography and a personal health questionnaire at the year 25 exam (2010–2011, n = 2788).

Main Measures

NAFLD was defined as liver attenuation ≤ 51 Hounsfield units after exclusion of other causes of liver fat. Participants were considered “NAFLD aware” if they reported being told previously by a doctor or nurse that they had “fatty liver.”

Key Results

NAFLD prevalence was 23.9%. Only 16 of 667 (2.4%) participants with CT-defined NAFLD were aware of a NAFLD diagnosis. NAFLD aware participants were more likely to be white (81.3% vs. 53.5%, p = 0.03) and have the metabolic syndrome (87.5% vs. 59.3%, p = 0.02) and/or hypertension (75.0% vs. 50.2%, p = 0.05). In multivariable analyses adjusted for demographics, metabolic syndrome and hypertension remained predictive of NAFLD awareness.

Conclusion

There is low awareness of NAFLD among individuals with hepatic steatosis on imaging, even among those with metabolic risk factors. These findings highlight an opportunity to raise public and practitioner awareness of NAFLD with the goal of increasing diagnosis and implementing early treatment strategies.

KEY WORDS

NAFLD computed tomography NASH metabolic syndrome hepatic steatosis 

Notes

Acknowledgments

The authors thank the participants of the CARDIA Study for their long-term commitment and important contributions to the study.

Funding Information

The CARDIA Study is supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the University of Alabama at Birmingham (HHSN268201800005I & HHSN268201800007I), Northwestern University (HHSN268201800003I), University of Minnesota (HHSN268201800006I), and Kaiser Foundation Research Institute (HHSN268201800004I). Dr. VanWagner is supported by the National Institutes of Health (KL2TR001424) and the NHLBI (K23HL136891). Dr. Carr is supported by the National Institutes of Health (R01HL098445).

Compliance with Ethical Standards

Informed consent was obtained at each follow-up examination. Institutional Review Board (IRB) approval was obtained from all study sites prior to data collection.

Conflict of Interest

The authors declare that they do not have a conflict of interest.

Supplementary material

11606_2019_5340_MOESM1_ESM.docx (15 kb)
ESM 1 (DOCX 15 kb)

References

  1. 1.
    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.CrossRefGoogle Scholar
  2. 2.
    Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9(6):524–30 e1; quiz e60.CrossRefGoogle Scholar
  3. 3.
    Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.CrossRefGoogle Scholar
  4. 4.
    Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113–21.CrossRefGoogle Scholar
  5. 5.
    Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):371–9.CrossRefGoogle Scholar
  6. 6.
    Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR, Jr., et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. J Clin Epidemiol. 1988;41(11):1105–16.CrossRefGoogle Scholar
  7. 7.
    VanWagner LB, Ning H, Lewis CE, Shay CM, Wilkins J, Carr JJ, et al. Associations between nonalcoholic fatty liver disease and subclinical atherosclerosis in middle-aged adults: the Coronary Artery Risk Development in Young Adults Study. Atherosclerosis. 2014;235(2):599–605.CrossRefGoogle Scholar
  8. 8.
    Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: its usefulness in predicting the presence of diffuse liver disease. Radiology. 1980;137(3):727–9.CrossRefGoogle Scholar
  9. 9.
    Kodama Y, Ng CS, Wu TT, Ayers GD, Curley SA, Abdalla EK, et al. Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol. 2007;188(5):1307–12.CrossRefGoogle Scholar
  10. 10.
    Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239(1):105–12.CrossRefGoogle Scholar
  11. 11.
    Warnick GR. Enzymatic methods for quantification of lipoprotein lipids. Methods Enzymol. 1986;129:101–23.CrossRefGoogle Scholar
  12. 12.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.PubMedGoogle Scholar
  13. 13.
    Grundy SM, Brewer HB, Jr., Cleeman JI, Smith SC, Jr., Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13–8.PubMedGoogle Scholar
  14. 14.
    Parker ED, Schmitz KH, Jacobs DR, Dengel DR, Schreiner PJ. Physical activity in young adults and incident hypertension over 15 years of follow-up: the CARDIA study. Am J Public Health. 2007;97(4):703–9.CrossRefGoogle Scholar
  15. 15.
    Cleveland E, Bandy A, VanWagner LB. Diagnostic challenges of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Clin Liver Dis (Hoboken). 2018;11(4):98–104.CrossRefGoogle Scholar
  16. 16.
    Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Dig Dis Sci. 2016;61(7):2108–17.CrossRefGoogle Scholar
  17. 17.
    European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.CrossRefGoogle Scholar
  18. 18.
    Wong VW, Chalasani N. Not routine screening, but vigilance for chronic liver disease in patients with type 2 diabetes. J Hepatol. 2016;64(6):1211–3.CrossRefGoogle Scholar
  19. 19.
    Wright AP, Desai AP, Bajpai S, King LY, Sahani DV, Corey KE. Gaps in recognition and evaluation of incidentally identified hepatic steatosis. Dig Dis Sci. 2015;60(2):333–8.CrossRefGoogle Scholar
  20. 20.
    Ghevariya V, Sandar N, Patel K, Ghevariya N, Shah R, Aron J, et al. Knowing What’s Out There: Awareness of Non-Alcoholic Fatty Liver Disease. Front Med (Lausanne). 2014;1:4.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Leung CM, Lai LS, Wong WH, Chan KH, Luk YW, Lai JY, et al. Non-alcoholic fatty liver disease: an expanding problem with low levels of awareness in Hong Kong. J Gastroenterol Hepatol. 2009;24(11):1786–90.CrossRefGoogle Scholar
  22. 22.
    Wieland AC, Mettler P, McDermott MT, Crane LA, Cicutto LC, Bambha KM. Low awareness of nonalcoholic fatty liver disease among patients at high metabolic risk. J Clin Gastroenterol. 2015;49(1):e6-e10.CrossRefGoogle Scholar
  23. 23.
    Said A, Gagovic V, Malecki K, Givens ML, Nieto FJ. Primary care practitioners survey of non-alcoholic fatty liver disease. Ann Hepatol. 2013;12(5):758–65.CrossRefGoogle Scholar
  24. 24.
    Wieland AC, Quallick M, Truesdale A, Mettler P, Bambha KM. Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58(10):2809–16.CrossRefGoogle Scholar
  25. 25.
    Bergqvist CJ, Skoien R, Horsfall L, Clouston AD, Jonsson JR, Powell EE. Awareness and opinions of non-alcoholic fatty liver disease by hospital specialists. Intern Med J. 2013;43(3):247–53.CrossRefGoogle Scholar
  26. 26.
    VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15(2):75–85.CrossRefGoogle Scholar
  27. 27.
    Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008;49(4):608–12.CrossRefGoogle Scholar
  28. 28.
    Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13(4):643–54 e1-9; quiz e39-40.CrossRefGoogle Scholar
  29. 29.
    Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2014.Google Scholar
  30. 30.
    Cho CS, Curran S, Schwartz LH, Kooby DA, Klimstra DS, Shia J, et al. Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surg. 2008;206(3):480–8.CrossRefGoogle Scholar
  31. 31.
    Boyce CJ, Pickhardt PJ, Kim DH, Taylor AJ, Winter TC, Bruce RJ, et al. Hepatic steatosis (fatty liver disease) in asymptomatic adults identified by unenhanced low-dose CT. AJR Am J Roentgenol. 2010;194(3):623–8.CrossRefGoogle Scholar
  32. 32.
    Pickhardt PJ, Park SH, Hahn L, Lee SG, Bae KT, Yu ES. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2012;22(5):1075–82.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  • Erin R. Cleveland
    • 1
  • Hongyan Ning
    • 2
  • Miriam B. Vos
    • 3
  • Cora E. Lewis
    • 4
  • Mary E. Rinella
    • 1
  • John Jeffrey Carr
    • 5
  • Donald M. Lloyd-Jones
    • 2
    • 6
  • Lisa B. VanWagner
    • 1
    • 2
    Email author
  1. 1.Department of Medicine—Division of Gastroenterology & Hepatology Northwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Department of Preventive MedicineNorthwestern University Feinberg School of MedicineChicagoUSA
  3. 3.Department of Pediatrics—Division of Gastroenterology, Hepatology & NutritionEmory UniversityAtlantaUSA
  4. 4.Department of Medicine—Division of Preventive MedicineUniversity of Alabama BirminghamBirminghamUSA
  5. 5.Department of RadiologyVanderbilt UniversityNashvilleUSA
  6. 6.Department of Medicine—Division of CardiologyNorthwestern University Feinberg School of MedicineChicagoUSA

Personalised recommendations